Check for updates

scientific reports

Published online: 20 January 2023

OPEN Author Correction: Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcRand ACE2-positive cells

Jun Shimizu, Tadahiro Sasaki, Ritsuko Koketsu, Ryo Morita, Yuka Yoshimura, Ami Murakami, Yua Saito, Toshie Kusunoki, Yoshihiro Samune, Emi E. Nakayama, Kazuo Miyazaki & Tatsuo Shioda

Correction to: Scientific Reports https://doi.org/10.1038/s41598-022-19993-w, published online 16 September 2022

The original version of this Article contained an error, where the mention of "mRNA" was inappropriate.

As a result, in the Introduction,

"Therapeutic Ab drugs targeting SARS-CoV-2 S-protein have shown high preventive efficacy against disease development^{1,2,3}. In addition, current SARS-CoV-2 mRNA vaccines for humans also target the S-protein on viruses as a critical antigen⁴. These mRNA vaccines generate robust neutralizing Abs^{5,6,7}, but for both Ab drugs and vaccines targeting the S-protein, the possible induction of Ab-dependent enhancement (ADE) of infection is a concern^{8,9,10,11}."

now reads:

"Therapeutic Ab drugs targeting SARS-CoV-2 S-protein have shown high preventive efficacy against disease development^{1,2,3}. In addition, current SARS-CoV-2 vaccines for humans also target the S-protein on viruses as a critical antigen⁴. These vaccines generate robust neutralizing Abs^{5,6,7}, but for both Ab drugs and vaccines targeting the S-protein, the possible induction of Ab-dependent enhancement (ADE) of infection is a concern^{8,9,10,11}."

The original Article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2023